Thread by @remap_cap

@remap_cap is proud to announce the findings of IL-6 blockade in critically ill patients with #COVID19.
medrxiv.org/cgi/content/sh… (1/10)

353 patients randomized to #tocilizumab, 48 to #sarilumab, and 402 to control.
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)

Mortality was 28% with tocilizumab, 22.2% for sarilumab (combined 27.3%), and 35.8% for control, with benefit of IL-6 blockade on all secondary outcomes collected. (3/10)

At the time of randomization, 28.8% were on high-flow nasal cannulae, 41% were on non-invasive ventilation, and 29.4% were invasively ventilated. 32.8% received remdesivir. (4/10)

Why different than the other Il-6 studies in COVID19? Exclusively critically ill population and the possibly additive effect of steroids may explain (majority received steroids) (5/10)

There was no difference observed based on CRP tercile at time of randomization.

There was no increase in adverse events in the IL-6 antagonism group, in the open-label design (6/10)

These results have been submitted for peer review and should be considered preliminary; minor changes may occur with further follow-up and analysis (7/10)

The full protocol and statistical analysis plan are available here remapcap.org/protocol-docum… (8/10)

Thanks to patients who continue to advance our knowledge of this disease and our sponsors and funders:
@PREPARE_EUROPE @RECOVER_EUROPE @UMCUtrecht @anzicrc @anzicsctg @ClinResearchNZ @HRCNewZealand @capticcanada @SMHcriticalcare @CCCTG_ @CIHR_IRSC @GCAResearch (9/10)

@APPRISE_CRE @minderoo @ICNARC
@NIHRresearch @Asiacritical @UPMC @NHLBI @wellcometrust and Translational Breast Cancer Research Consortium #TBCRC (10/10)